Medicines | Horizonscan geneesmiddelen

Abnobaviscum 900 ^G Durvalumab ^IND Enfortumab vedotin ^IND Erdafitinib Inbakicept

Nivolumab

Extension of indication to include in combination with cisplatin-based chemotherapy the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. ^IND OPDIVO in combination with cisplatin-based chemotherapy is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. ^IND

Sacituzumab Govitecan ^IND Sasanlimab

Dabrafenib / trametinib Paclitaxel trevatide Vorasidenib

Atezolizumab ^IND Camizestrant Capivasertib

Datopotamab deruxtecan

Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with locally recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. ^IND Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with inoperable or metastatic HR-Positive, HER2-negative Breast Cancer who have been treated with one or two prior lines of systemic chemotherapy. ^IND

Elacestrant Inavolisib ^IND Olaparib ^IND Paclitaxel Palbociclib ^IND Ribociclib ^IND Sacituzumab govitecan ^IND

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy ^IND Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. ^IND Extension of indication to include treatment of HER2-low/ultra-low hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting. ^IND

Vepdegestrant

Cadonilimab Dostarlimab ^IND Olaparib ^IND Tisotumab vedotin

Fruquintinib Nivolumab ^IND Pembrolizumab / favezelimab Trifluridine / tipiracil ^IND

Atezolizumab ^IND Leukocyte interleukin Tislelizumab ^IND Xevinapant

Abexinostat Belzutifan Cabozantinib ^IND

Atezolizumab ^IND

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). ^IND

Namodenoson Tremelimumab

Adagrasib Alectinib ^IND

Amivantamab

Amivantamab in combination with carboplatin and pemetrexed for the first‑line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations. ^IND Amivantamab in combination with chemotherapy is indicated for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) after osimertinib failure. ^IND Amivantamab in combination with lazertinib is indicated for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). ^IND

Atezolizumab

Subcutaneous formulation of atezolizumab for treatment of PD-(L)-1 Cancer Immunotherapy in multiple tumor types. ^IND Extension of indication to include first-line treatment of adult patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy and who do not have EGFR mutant or ALK-positive disease, who have: locally advanced unresectable NSCLC not amenable for definitive chemoradiotherapy, or metastatic NSCLC. ^IND

Aumolertinib (mesilate) Cobolimab

Datopotamab deruxtecan

Datopotamab deruxtecan, in combination with Pembrolizumab, is indicated for the treatment of adult patients with advanced or metastatic NSCLC without actionable genomic alterations whose tumor has high programmed death-ligand 1 (PD-L1) expression (tumor proportion score; TPS ≥50%) and who have not previously received systemic therapy for advanced or metastatic NSCLC. ^IND Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer, who have received at least one systemic therapy

Domvanalimab

Durvalumab

Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND 1L advanced NSCLC ^IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. ^IND Extension of indication to include IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements. ^IND

Encorafenib ^IND Ipilimumab ^IND Lazertinib Lenvatinib ^IND Nintedanib ^G

Nivolumab

OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥1% ^IND Extension of indication to include OPDIVO for the treatment of patients with resectable stage II-IIIB non-small cell lung cancer ^IND

Ociperlimab

Osimertinib

Osimertinib in combination with pemetrexed and platinum based chemotherapy for locally advanced (clinical stage IIIB, IIIC) or metastatic Non-Small Cell Lung Cancer (NSCLC) (clinical stage IVA or IVB) or recurrent Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. ^IND Stage III unresectable Epidermal Growth Factor Receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) ^IND Extension of indication to include treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy. ^IND

Pembroliuzmab ^IND

Pembrolizumab

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum‑based chemotherapy. ^IND Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non‑small cell lung carcinoma at high risk of recurrence in adults ^IND

Retifanlimab ^IND Sacituzumab Govitecan ^IND Serplulimab Sugemalimab

Tiragolumab

In combination with atezolizumab for first line treatment of locally advanced, unresectable Stage III Non-small cell lung cancer in adults and elderly who have no progression during or following concurrent platinum-based chemoradiotherapy. Tiragolumab in combination with Atezolizumab for first line treatment of locally advanced unresectable or metastatic high PD-L1, EGFR-negative, ALK-negative Non-small cell lung cancer in adults and elderly.

Tislelizumab

Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC Tizveni in combination with pemetrexed and platinum‑containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC Extension of indication to include treatment of adult patients with non-small cell lung cancer (NSCLC) in combination and as monotherapy ^IND

Toripalimab ^IND Trastuzumab deruxtecan ^IND Tremelimumab

AL102 Afamitresgene autoleucel Catequentinib Efbemalenograstim alfa Entrectinib ^IND Futibatinib Melphalan hydrochloride NY-ESO-1 autologous engineered TCR-T cells Nirogacestat Nivolumab ^IND

Pembrolizumab

Indication for treatment in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults. ^IND Extension of indication to include in combination with pemetrexed and platinum chemotherapy the first -line treatment of adults and adolescents aged 12 years and older with unresectable advanced or metastatic malignant pleural mesothelioma. ^IND

Repotrectinib

Retifanlimab

Patiënten met inoperabele, lokaal gevorderd of gemetastaseerd plaveiselcarcinoom van het anale kanaal. Zynyz is indicated as monotherapy for the first‑line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy

Selinexor ^IND Sugemalimab ^IND Tebentafusp

Tislelizumab

Tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy. Extension of indication to include in combination with platinum-based chemotherapy the first-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC)

Toripalimab

Toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) Toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (“ESCC”)

Dostarlimab ^IND Mirvetuximab soravtansine Olaparib ^IND Rucaparib ^IND

Gemcitabine Irinotecan in gepegyleerde liposomen ^IND

Aglatimagene besadenovec Atezolizumab ^IND Degarelix ^G Enzalutamide ^IND Lutetium (177lu) vipivotide tetraxetan Niraparib ^IND Niraparib / abirateron Olaparib ^IND Radium-223 ^IND Relugolix Rucaparib ^IND Talazoparib ^IND

Daromun

Ipilimumab

Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma. ^IND Neoadjuvant Ipilimumab Plus Nivolumab in Macroscopic Stage III Melanoma. ^IND

Lifileucel Nivolumab/relatlimab/hyaluronidase Ph20 Relatlimab / nivolumab Tucidinostat

Catumaxomab Domvanalimab

Pembrolizumab

Extension of indication for treatment with pembrolizumab plus trastuzumab in combination with standard of care chemotherapy for adults with HER2 positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma ^IND Treatment in the neoadjuvant or adjuvant setting of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. ^IND

Tislelizumab ^IND Trastuzumab deruxtecan ^IND Zolbetuximab

Selpercatinib ^IND

MDM2-p53 antagonist Selpercatinib ^IND Trastuzumab Deruxtecan ^IND

Belzutifan Decitabine / cedazuridine ^IND Mycofenolaatmofetil ^IND Pembrolizumab ^IND

Oncology

Bladder cancer

Nivolumab

Brain cancer

Breast cancer

Datopotamab deruxtecan

Trastuzumab deruxtecan

Cervical cancer

Colon cancer

Head and neck cancer

Kidney cancer

Liver cancer

Durvalumab

Lung cancer

Amivantamab

Atezolizumab

Datopotamab deruxtecan

Durvalumab

Nivolumab

Osimertinib

Pembrolizumab

Tiragolumab

Tislelizumab

Oncology other

Pembrolizumab

Retifanlimab

Tislelizumab

Toripalimab

Ovarian cancer

Pancreatic cancer

Prostate cancer

Skin cancer

Ipilimumab

Stomach cancer

Pembrolizumab

Thyroid cancer

Tumour agnostic medication

Unknown

Service

About this site